Roche faces sales slide when AVASTIN <b>breast cancer</b> loses license

Translate Request has too much data
Parameter name: request
Translate Request has too much data
Parameter name: request
Roche Faces Sales Slide If Avastin Loses Breast Cancer License - WSJ.com More BigCharts Virtual Stock Exchange WSJ Asia WSJ Europe WSJ Portuguese WSJ Spanish WSJ Chinese WSJ Japanese WSJ Radio Financial News WSJ Lifestyle Brands WSJwine SEARCH Friday, August 20, 2010 As of 12:13 PM EDT | The Wall Street Journal Business Welcome, Logout My Account My Journal Help Message Center ( new)
U.S. Edition Home ? More

WSJ.com is available in the following editions and languages:

U.S. Asia India China Japan Europe Americas en Español em Português Register for FREE Register for FREE Thank you for registering.

We sent an email to:

Please click on the link inside the email to complete your registration

Please register to gain free access to WSJ tools.

An account already exists for the email address entered.

Forgot your username or password?

This service is temporary unavailable due to system maintenance. Please try again later.

The username entered is already associated with
another account. Please enter a different username

The email address you have entered is already in use.
Please re-enter the email address.

First Name Last Name Email (your email address will be your login)Confirm Email Create a Password Confirm Password Company Size (Optional) Please make a selection 1-99 100-499500-9991,000-2,4992,500-4,9995,000-9,99910,000-14,99915,000-24,99925,000+Not Applicable

From time to time, we will send you e-mail announcements on new features and special offers from The Wall Street Journal Online.

Create a profile for me in the Journal Community

Why Register?

Privacy Policy | Terms & Conditions

As a registered user of The Wall Street Journal Online, you will be able to:

Setup and manage your portfolio

Personalize your own news page

Receive and manage newsletters

Login/Register to set your edition Today's Paper Video Blogs Journal Community

Log In Log In Login Password Log in Your login is either a username or an email address.

Keep me logged in. Forgot your password?

World » More

World » More

Loading… U.S. » More

U.S. » More

Loading… New York » More

New York » More

Loading… Business » More

Business » More

Loading… Markets » More

Markets » More

Loading… Tech » More

Tech » More

Loading… Personal Finance » More

Personal Finance » More

Loading… Life & Culture » More

Life & Culture » More

Loading… Opinion » More

Opinion » More

Loading… Careers » More

Careers » More

Loading… Real Estate » More

Real Estate » More

Loading… Small Business » More

Small Business » More

Loading… Asia Europe Earnings Economy Health Law Autos Management Media & Marketing Energy   More Industries   Accounting Advertising Airlines Banking Chemicals Computer Hardware Computer Software Consumer Products Defense & Aerospace Broadcasting & Entertainment Financial Services & Insurance Food & Tobacco Hospitality Industrial Goods & Services Media Agencies Paper & Forest Products Pharmaceutical & Biotech Real Estate Retail Semiconductors Transportation Close

Dow Jones Reprints: This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers, use the Order Reprints tool at the bottom of any article or visitwww.djreprints.com

See a sample reprint in PDF format.Order a reprint of this article nowDECEMBER 8, 2010, 12:15 P.M. ETRoche Faces Sales Slide If Avastin Loses Breast Cancer License ArticleCommentsmore in Business »

ZURICH (Dow Jones)--Roche Holding AG (ROG.VX), the world's biggest maker of oncology drugs, risks losing more than 1 billion Swiss francs ($1 billion) in sales next year if U.S. and EU regulators decide to revoke top-selling Avastin's license to treat breast cancer patients.

Analysts expect the sales drop to be between CHF500 million and CHF1.5 billion, depending on how harsh regulators will curtail the drug's use. The larger figure would represent a 25% decline for Avastin, which is used for treating lung, kidney, colorectal and breast cancer. It is Roche's best-selling medicine, contributing more than 10% to overall sales of ...

Email Printer Friendly Order Reprints Share:

facebook

Twitter

Digg

StumbleUpon

Viadeo

Orkut

Yahoo! Buzz

Fark

Reddit

LinkedIn

del.icio.us

MySpace

 

Copyright 2010 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit

www.djreprints.com

Back To Back ToMSN Money HomepageMSN Money InvestingMost Popular ReadEmailedVideoCommentedSearches1.Consumer Reports Thumps AT&T 2.Obama Woos Wary Party on Tax Deal3.Opinion: Best of the Web Today: Birther of The Nation4.Hackers Strike Back to Support WikiLeaks5.Opinion: Obamanomics Takes a Holiday1.A Device to Kill Cancer, Lift Revenue2.New Rules for Food Allergies3.Consumer Reports Thumps AT&T 4.Baby May Be Giving You Mommy Thumb5.Hollywood's Guide to the Bowl Games1.Why Luxury Car Buyers May Expect a Wait2.AM Report: Obama Faces Liberal Critics of Tax Deal3.The New Men's Club: Urology Radiation Centers4.And the Loo of the Year Award Goes to...5.Opinion Journal: A Good Tax Deal?1.Deal Struck on Tax Package960 comments2.Obama Woos Wary Party on Tax Deal646 comments3.Tax Deal Within Reach455 comments4.China Clones, Sells Russian Fighter Jets383 comments5.Opinion: Prosecute Assange Under the Espionage Act296 comments 1. Facebook 2. economy 3. Apple 4. Mad Men 5. China Most Read Articles Feed Most Emailed Feed Most Popular Video Feed Most Commented FeedMost Popular Feeds Editors' PicksFeisty Campaigner Drew Sympathy Amid TragedyWhy Narcissism Defines Our TimeBig Bear Jackpot: Q&A With New Jersey HunterCramming More Into 24 HoursGM To Demonstrate Space Robonaut 'R2' (Video)Albert Haynesworth: 335 Pounds of DramaCan a Michelin Star Boost Business?'Birds' Book Soars to Record SaleJudge's Call Divides DodgersSame-Sex Benefits Ban Roils El PasoEpic History of the Holocaust ReturnsNurturing Creativity in the Next GenerationWine 101: Old World vs. NewToyota's Prius to Become Top Japan Seller — EverWalking Away from Your Home for DummiesWhat to Do With an Orphaned Franchise?Videoprevious nextOpinion Journal Opinion Journal: Hunting Assange4:15Opinion Journal Opinion Journal: A Good Tax Deal?9:42Opinion Journal Opinion Journal: Dodging Hillary3:46Opinion Journal Opinion Journal: Washington's Tax Deal8:35Opinion Journal Opinion Journal: Worst Job Market in Decades8:18Opinion Journal Opinion Journal: The FDA Power Grab5:44Opinion Journal WikiLeaks R Us2:34Opinion Journal Opinion Journal: Who Will Run Congress?2:25Opinion Journal Opinion Journal: Democrats Get Nervous7:08Opinion Journal Opinion Journal: The Haitian Elections 4:46Opinion Journal Opinion Journal: WikiLeaked8:36Opinion Journal Opinion Journal: How WSJ Creates Its Op-Ed Page6:27Opinion Journal Opinion Journal: Corruption in India2:57Opinion Journal Opinion Journal: Think TSA is Bad Now?6:21Opinion Journal Opinion Journal: Guide to Insider Trading4:47 Most Recommended CommentsComments CommentersCommenters 1. “
I started and own a business...;” - Mark Beck 199 Recommendations 2. “The reason we have a federal...;” - Justin Hertog 79 Recommendations 3. “Great idea! Let's all quit our...;” - Kathy Ebbert 77 Recommendations 4. “Rules for legislating:
1....;” - Jared Potter 73 Recommendations 5. “You point out something that the...;” - Jack Davidson 71 Recommendations Peter Venetoklis 852 Recommendations jean balloon 655 Recommendations Greg Liautaud 519 Recommendations Eric Nelson 510 Recommendations Jonathan Murray 505 Recommendations Most Active Discussions Journal Community Question of the Day

Should Congress pass a plan which extends tax cuts for all Americans, lowers payroll taxes for 2011 and extends unemployment benefits?

The Obama Administration

Should the Bush-era tax cuts for all income levels be extended?

Libertarians

What do you think about Kyle Townsend’s libertarian social structure?

Libertarians

Is a Libertarian Society a Pipedream?

Question of the Day

Would you use an Internet “do-not-track” tool if it were included in your Web browser?

See all Discussion Groups More in BusinessOverhaul of Oil Industry UrgedNew Faces, Ties in Trading ProbeKFC Savors Potential in AfricaInvestors Pile Into CommoditiesFortune Brands Plans to Split Up null Email Newsletters and Alerts

The latest news and analysis delivered to your in-box. Check the boxes below to sign up.

WSJ.com Email Features Real Time Economics Newsletter News AlertSubmit The email address null is already associated with another account. Please enter a different email address:

Enter Your Email

Sign UpNew! To sign up for Keyword or Symbol Alerts click here.To view or change all of your email settings, visit the Email Setup Center.

Thank you !
You will receive in your inbox.

To view or change all of your email settings, visit the Email Setup Center. null Email Newsletters and Alerts

The latest news and analysis delivered to your in-box. Check the boxes below to sign up.

WSJ.com Email Features This Week's Most Popular On the Editorial PageSubmit The email address null is already associated with another account. Please enter a different email address:

Enter Your Email

Sign UpManage Email Preferences

Thank you !
You will receive in your inbox.

Manage Email Preferences Editors' PicksFeisty Campaigner Drew Sympathy Amid TragedyWhy Narcissism Defines Our TimeBig Bear Jackpot: Q&A With New Jersey HunterCramming More Into 24 HoursGM To Demonstrate Space Robonaut 'R2' (Video)Albert Haynesworth: 335 Pounds of DramaCan a Michelin Star Boost Business?'Birds' Book Soars to Record SaleJudge's Call Divides DodgersSame-Sex Benefits Ban Roils El PasoEpic History of the Holocaust ReturnsNurturing Creativity in the Next GenerationWine 101: Old World vs. NewToyota's Prius to Become Top Japan Seller — EverWalking Away from Your Home for DummiesWhat to Do With an Orphaned Franchise? WSJ Web Slice CONTENT LINKS TO ACTUAL PAGE CONTAINING WEB SLICE FUNCTIONALITY. 15back to top WSJ.com Account:My AccountSubscriber Billing InfoCreate an Account:Register for FreeSubscribe to WSJ.comSign up for WSJ ProfessionalHelp & Information Center:HelpCustomer ServiceContact UsNew on WSJ.comTour the new JournalAbout:News LicensingAdvertisingAdvertise LocallyConferencesAbout Dow JonesPrivacy Policy - UpdatedSubscriber Agreement & Terms of Use - UpdatedCopyright PolicyJobs at WSJ.comFuture Leadership ProgramWSJ.com:Site MapHomeWorldU.S.New YorkBusinessMarketsMarket DataTechPersonal FinanceLife & CultureOpinionAutosCareersReal EstateSmall BusinessStudent JournalCorrectionsTools & Formats:Today's PaperVideo CenterGraphicsColumnsBlogsTopicsGuidesAlertsNewslettersMobileTablet EditionPodcastsRSS FeedsJournal Community- Message CenterWSJ on TwitterWSJ on FacebookWSJ on FoursquareMy JournalPortfolioDigital NetworkWSJ.comMarketwatch.comBarrons.comSmartMoney.comAllThingsD.comFINS: Finance, IT jobs, Sales jobsBigCharts.comVirtual Stock ExchangeWSJ RadioProfessorJournal.comWSJ U.S. EditionWSJ Asia EditionWSJ Europe EditionWSJ India PageForeign language editions:WSJ ChineseWSJ JapaneseWSJ PortugueseWSJ SpanishACAP EnabledCopyright ©2010 Dow Jones & Company, Inc. All Rights Reserved

View the original article here